DFPP療法における安全性とその留意点(<特集>アフェレシスにおけるセイフティーマネジメント) Safety Management of the DFPP Treatment

    • 江口 圭 Eguchi Kei
    • 東京女子医科大学臨床工学部 Department of Clinical Engineering and Tokyo Women's Medical University
    • 横井 良 Yokoi Ryo
    • 東京女子医科大学臨床工学部 Department of Clinical Engineering and Tokyo Women's Medical University

    • 秋葉 隆 Akiba Takashi
    • 東京女子医科大学腎臓病総合医療センター血液浄化療法科 Division of Blood Purification, Kidney Center, Tokyo Women's Medical University

抄録

Double-filtration plasmapheresis (DFPP) has been widely used clinically as apheresis therapy for various autoimmune diseases, blood-group-incompatible renal transplantation, familial hypercholesterolemia, arteriosclerosis obliterans, etc. DFPP is procedurally complicated, as compared to hemodialysis, because it is designed to separate plasma components in two stages. A firm knowledge and fixed technique are required for safe execution of the treatment. Unless the albumin concentration in the substitute fluid is adequate, for instance, there is the risk of hypotension and cardiac overload, due to a decrease of the colloid osmotic pressure. Unless the amount of substitute fluid handled is adequate, efficient removal of pathogenic substances cannot be expected. The method of administering anticoagulants also needs to be altered according to the treatment indication. It is important to establish proper treatment conditions tailored to individual patients. This article describes the importance of a control and monitoring system as safety management of the apparatus and the establishment of proper treatment conditions (substitute fluid, anticoagulants, etc.) for the safety of the staff involved with the treatment.

収録刊行物

日本アフェレシス学会雑誌   [巻号一覧]

日本アフェレシス学会雑誌 24(1), 39-46, 2005-02-28  [この号の目次]

日本アフェレシス学会

プレビュー

プレビュー

各種コード

  • NII論文ID(NAID) :
    110003161377
  • NII書誌ID(NCID) :
    AA11604174
  • 本文言語コード :
    JPN
  • ISSN :
    13405888
  • 収録DB :
    NII-ELS 

書き出し